FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

· · · · · · · · · · · · · · · · · · ·	D.O. 200 10	

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average b	urden							

hours per response

0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Christopher Nishan Garabedian</u>						2. Issuer Name <b>and</b> Ticker or Trading Symbol Sarepta Therapeutics, Inc. [ SRPT ]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  X Director 10% Owner					
(Last) (First) (Middle) 215 FIRST STREET, SUITE 7						3. Date of Earliest Transaction (Month/Day/Year) 02/27/2015									Officer (give title below)  Other (specify below)  President and CEO				
(Street) CAMBR (City)		IA State)	02142 (Zip)		4.	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Indi Line) X	vidual or Joint/Group Filing (Check Applicable  Form filed by One Reporting Person  Form filed by More than One Reporting  Person				
(Oity)	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																		
1. Title of Security (Instr. 3)  2. Transa Date (Month/D				action	Execution Date,			Transaction Disposed Of Code (Instr.			ies Acquired (A) or Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership	
									Code	v	Amount	(A) or (D)		e	Reported Transaction(s) (Instr. 3 and 4)				Instr. 4)
Common Stock 02/2				02/27	7/201	7/2015		P		800	A \$1		1.815	29,5	,552 <sup>(1)</sup>		D		
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security		3A. Deemed Execution D if any (Month/Day/	ate, Tr	ransa ode (I		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercis Expiration Date (Month/Day/Ye			7. Title and Amor of Securities Underlying Derivative Securi (Instr. 3 and 4)			8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction	e s lly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
				С	ode	v	(A)	(D)	Date Exercisab		Expiration Date Title Amou		er	(Instr. 4)		on(s)			
Incentive Stock Option (right to buy)	\$13.9	02/27/2015			A		7,196		(2)	0	12/27/2025	Common Stock	7,19	96	\$0.0	7,196	5	D	
Non- Qualified Stock Option (right to	\$13.9	02/27/2015			A		365,804		(2)	0	2/27/2025	Common Stock	365,8	804	\$0.0	365,80	)4	D	

## **Explanation of Responses:**

- 1. Includes shares acquired under the Sarepta Therapeutics, Inc. 2013 Employee Stock Purchase Plan; 674 shares were acquired on August 29, 2014 at a price of \$19.4905 and 800 shares were acquired on February 27, 2015.
- 2. 25% of the option granted vests and is exercisable on the first anniversary of the date of grant and 1/48th of the total granted option will vest and become exercisable on each monthly anniversary thereafter, such that the option will be fully vested and exercisable on the fourth anniversary of the date of grant.

By: David Tyronne Howton For: Christopher Garabedian

03/03/2015

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.